Ocumension Therapeutics (SEHK: 1477)
Health Care · Pharmaceuticals · CN
HK$5.29
-0.66% today · -44.9% 1Y
Ocumension Therapeutics (SEHK: 1477) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $549.65M and employs 552 people.
Over the last twelve months the share price has lost 44.9%, trading between 4.04 and 12.07.
Tweenvest scores Ocumension Therapeutics across four factors: quality 47/100, value 69/100, growth 100/100. Its strongest factor is growth.
1477 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $549.65M
- Revenue (TTM)
- $115.00M
- P/E
- —
- EPS
- -0.20
- Dividend yield
- —
- Beta (5Y)
- 0.43
- 52-week high
- HK$12.07
- 52-week low
- HK$4.04
- Avg volume (3M)
- —
- Shares outstanding
- 815.38M
- Employees
- 552
- Next earnings
- —
About Ocumension Therapeutics
Based in the People's Republic of China, Ocumension Therapeutics functions as a dedicated ophthalmic pharmaceutical platform. This company, along with its subsidiaries, is committed to the research, progression, and market introduction of therapeutic solutions for individuals with various eye conditions. Its extensive product offerings target treatments for disorders such as blepharitis, infectious and allergic conjunctivitis, dry eye syndrome, cataracts, glaucoma, ocular hypertension, post-surgical inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, corneal graft rejection, myopia, and optic neuritis. By December 31, 2021, Ocumension Therapeutics boasted a pipeline of 20 drug assets. The company, founded in 2017, maintains its headquarters in Suzhou, China.
- Founded
- 2017
- Listed since
- Jul 10, 2020
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.